New stock news | Anhui Huaheng Biotechnology Co., Ltd. (688639.SH) Hong Kong IPO approved by China Securities Regulatory Commission.

On April 10, the International Cooperation Department of the China Securities Regulatory Commission issued the "Notice of Overseas Issuance and Listing Filing of Anhui Huaheng Biotechnology Co., Ltd." Anhui Huaheng Biotechnology Co., Ltd. (688639.SH) plans to issue no more than 31.9593 million shares of overseas common stock and list on the Hong Kong Stock Exchange. According to the prospectus, as a pioneer in global synthetic biotechnology, Anhui Huaheng Biotechnology Co., Ltd. focuses on research and development, large-scale production, and commercialization of bio-based products using biomanufacturing technology. The company has cutting-edge research and development capabilities, strong technological innovation capabilities, mature production capabilities, and is committed to transforming laboratory technology achievements into green, low-carbon, high-performance bio-based products and solutions to meet emerging application scenarios. With twenty years of deep cultivation in the field of biomanufacturing, the company has established a leading position in research and development, technology, and the market. According to Frost & Sullivan, the company is one of the most comprehensive bio-based product companies in the world to achieve commercialization of products through synthetic biotechnology; the company is the first in the world to industrialize anaerobic fermentation of series of amino acids (including L-proline and L-valine); and based on revenue in 2024, the company's market shares of L-proline and L-valine rank first globally.